IRTC
What one share of iRhythm Holdings holds
Surgical and Medical Instruments and Apparatus
Our principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that we believe allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology.
iRhythm Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $25.43 |
|---|---|
| Profit | −$0.43 |
| Capex (buildings and equipment) | $1.45 |
| Free cash flow | $1.20 |
| Cash and investments | $17.95 |
| Debt | $19.76 |
| Book value | $5.65 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $12.12 | −$3.95 | $0.52 | −$3.67 | — | — |
| 2017 | $4.38 | −$1.31 | $0.16 | −$0.82 | — | $3.39 |
| 2018 | $6.17 | −$2.11 | $0.22 | −$1.43 | — | $2.14 |
| 2019 | $8.49 | −$2.16 | $0.81 | −$1.68 | — | $5.07 |
| 2020 | $9.55 | −$1.58 | $0.49 | −$0.98 | — | $11.77 |
| 2021 | $11.01 | −$3.46 | $0.96 | −$2.24 | — | $9.48 |
| 2022 | $13.74 | −$3.88 | $1.00 | −$1.77 | — | $7.94 |
| 2023 | $16.14 | −$4.04 | $1.32 | −$2.97 | — | $6.79 |
| 2024 | $18.97 | −$3.63 | $1.09 | −$0.98 | — | $2.90 |
| 2025 | $23.35 | −$1.39 | $1.45 | $1.08 | — | $4.73 |